Response to Carboplatin and Paclitaxel in the treatment of hereditary breast ovarian cancer syndrome (HBOC): a case report

被引：0
|
作者：
Mehmood, Faisal [1 ]
Touseef, Mumtaz [2 ]
Ashraf, Amna [2 ]
Rai, Izza Ali [3 ]
机构：
[1] Combined Mil Hosp, Dept Radiol, Lahore, Pakistan
[2] Combined Mil Hosp, Dept Med, Lahore, Pakistan
[3] Combined Mil Hosp, Dept Vasc Surg, Lahore, Pakistan
来源：
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2024年 / 74卷 / 12期
关键词：
Hereditary breast ovarian cancer; Breast cancer; Ovarian cancer; HBOC; BRCA; PALB2; Chemotherapy; Carboplatin; Paclitaxel; PREVALENCE; MUTATIONS;
D O I：
10.47391/JPMA.20059
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The co-occurrence of primary breast cancer and primary ovarian cancer is an exceptional hereditary phenomenon and results from inherent mutations in critical genes like a unique case of hereditary breast-ovarian cancer syndrome (HBOC) reported in Combined Military Hospital, Lahore, Pakistan. It was marked by pathogenic variants in RAD51D, PALB2, CHEK1, and TP53 genes. Remarkably, the patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. This dynamic treatment not only led to nearly complete remission of high-grade ovarian serous cancer but also triggered regression in grade-2 invasive ductal breast cancer after just a few rounds of chemotherapy. Consequently, what started as palliative care evolved into a curative triumph.
引用
收藏
页码：2184 / 2187
页数：4
相关论文
共 50 条
  • [11] Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis
    Yoshida, Reiko
    BREAST CANCER, 2021, 28 (06) : 1167 - 1180
  • [12] Survey of physician awareness of oocyte and embryo cryopreservation in women with hereditary breast ovarian cancer (HBOC) syndrome
    West, A.
    Noyes, N.
    Pothuri, B.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S111 - S112
  • [13] Treatment of advanced ovarian cancer with carboplatin and paclitaxel in a patient undergoing hemodialysis: Case report and literature review
    Yang, Qing
    Han, Enhong
    Xu, Shanshan
    Xu, Yongxing
    Gao, Jianjun
    HEMODIALYSIS INTERNATIONAL, 2022, 26 (03) : E31 - E36
  • [14] HEREDITARY BREAST OVARIAN CANCER (HBOC): A PROJECT TO OPTIMIZE HEREDITARY CANCER PATHWAYS TO SAVE LIVES AND COSTS
    Mamede, Ana
    Garrido, Luzia
    Sousa, Liliana
    Oliveira, Renata
    Freixo, Joao Parente
    Louro, Pedro
    Costa, Susy
    Magalhaes, Andre
    Sousa, Sonia
    Fernandes, Susana
    Castedo, Sergio
    Oliveira, Carla
    MEDICINE, 2025, 104 (04)
  • [15] Response to paclitaxel and carboplatin in metastatic salivary gland cancer: A case report
    Ruzich, JC
    Ciesla, MC
    Clark, JI
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (04): : 406 - 410
  • [16] Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) for advanced breast cancer patients with high risk for Hereditary Breast and Ovarian Cancer Syndrome (HBOC).
    Sant'Ana, Rosane Oliveira
    de Lima Silva-Fernandes, Isabelle Joyce
    dos Santos Luciano, Maria Claudia
    de Barros Silva, Paulo Goberlanio
    Alves Lima, Marcos Venicio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] Challenges to the Paclitaxel/Carboplatin Algorithm in Ovarian Cancer Treatment
    Zorn, Kristin K.
    ONCOLOGY-NEW YORK, 2010, 24 (08): : 738 - 740
  • [18] Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer
    Neijt, JP
    du Bois, A
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 78 - 83
  • [19] PACLITAXEL PLUS CARBOPLATIN IN THE TREATMENT OF OVARIAN-CANCER
    HUININK, WT
    VEENHOF, C
    HELMERHORST, T
    BIERHORST, F
    DALESIO, O
    WINOGRAD, B
    DEPAUW, L
    PINEDO, HM
    SEMINARS IN ONCOLOGY, 1995, 22 (03) : 97 - 100
  • [20] Hereditary Breast and Ovarian Cancer Syndrome
    不详
    GYNECOLOGIC ONCOLOGY, 2009, 113 (01) : 6 - 11
12345